Literature DB >> 6565175

Lethality associated with incorporation of 5-fluorouracil into preribosomal RNA.

D Herrick, D W Kufe.   

Abstract

We have previously demonstrated a highly significant relationship between incorporation of 5-fluorouracil (FUra) into total cellular RNA and loss of clonogenic survival. The present study extends these findings by demonstrating a similar relationship between incorporation of FUra into preribosomal nuclear RNA (45 S and 32 S) and lethal cellular events. The results also demonstrate that the extent of FUra incorporation into preribosomal RNA (prRNA) correlates significantly with inhibition of maturation to cytoplasmic 28 S and 18 S rRNA. These findings suggest that the incorporation of FUra into prRNA alters recognition sites involved in the processing of 45 S and 32 S RNA. These data are further supported by our finding of an enhanced degradation of (FUra)prRNA by RNase III, an enzyme implicated in the maturation of Escherichia coli prRNA and T7 mRNA. These observations suggest that the incorporation of FUra into prRNA is responsible for altered processing to cytoplasmic rRNA and cell lethality.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6565175

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

Review 1.  RNA modifications: a mechanism that modulates gene expression.

Authors:  John Karijolich; Athena Kantartzis; Yi-Tao Yu
Journal:  Methods Mol Biol       Date:  2010

2.  RNA polymerase II transcripts as targets for 5-fluorouridine cytotoxicity: antagonism of 5-fluorouridine actions by alpha-amanitin.

Authors:  R Heimer; A C Sartorelli
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells.

Authors:  D A Greenhalgh; J H Parish
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

Review 5.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

6.  Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo.

Authors:  Xinliang Zhao; Yi-Tao Yu
Journal:  Nucleic Acids Res       Date:  2006-12-14       Impact factor: 16.971

7.  Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.

Authors:  Christina Leah B Kline; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-21

8.  5-Fluorouracil Treatment Alters the Efficiency of Translational Recoding.

Authors:  Junhui Ge; John Karijolich; Yingzhen Zhai; Jianming Zheng; Yi-Tao Yu
Journal:  Genes (Basel)       Date:  2017-10-31       Impact factor: 4.096

9.  Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.

Authors:  S J Freemantle; A L Jackman; L R Kelland; A H Calvert; J Lunec
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

10.  New insights into the RNA-based mechanism of action of the anticancer drug 5'-fluorouracil in eukaryotic cells.

Authors:  Laura Mojardín; Javier Botet; Luis Quintales; Sergio Moreno; Margarita Salas
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.